STAT+: Novo Nordisk accuses Hims & Hers of ‘illegal mass compounding’ over a cheaper version of Wegovy pill

Novo Nordisk has initiated legal action against Hims & Hers, a telehealth company, for allegedly infringing on a key patent related to its weight-loss drug, Wegovy. The lawsuit stems from Hims & Hers offering a compounded version of Wegovy at a lower price, which Novo Nordisk has criticized as an “untested knockoff.” The chief counsel of Novo Nordisk stated that telehealth companies and compounding pharmacies producing copycat versions of Wegovy should be “very, very much on notice” regarding the legal implications of their actions (Stat News). In response to the legal challenges and an ongoing investigation by the FDA, Hims & Hers has decided to cease the sale of its compounded weight-loss pill. The company had been marketing this alternative for €41, which drew significant criticism from Novo Nordisk. The Danish pharmaceutical company expressed concerns over the safety and efficacy of the unregulated compounded product, accusing Hims & Hers of “illegal mass compounding” (Stat News, Euronews). The situation has raised broader concerns within the pharmaceutical and telehealth industries regarding the legality and ethical implications of producing compounded medications that mimic established drugs. Novo Nordisk's actions signal a strong stance against what it perceives as infringement on its intellectual property and a potential risk to patient safety (Stat News). The outcome of this lawsuit could have significant repercussions for both companies and the compounding pharmacy sector as a whole (Stat News).